Cart
sales@molnova.com
Lys-SMCC-DM1
CAS No. 1281816-04-3
Lys-SMCC-DM1( Lys-Nε-MCC-DM1 )
Catalog No. M23445 CAS No. 1281816-04-3
DM1 is a tubulin inhibitor.?Lys-SMCC-DM1 is the active metabolite of DM1.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 622 | In Stock |
|
| 10MG | 897 | In Stock |
|
| 25MG | 1332 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLys-SMCC-DM1
-
NoteResearch use only, not for human use.
-
Brief DescriptionDM1 is a tubulin inhibitor.?Lys-SMCC-DM1 is the active metabolite of DM1.?
-
DescriptionDM1 is a tubulin inhibitor.?Lys-SMCC-DM1 is the active metabolite of DM1.?
-
In Vitro——
-
In Vivo——
-
SynonymsLys-Nε-MCC-DM1
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetMicrotubule/Tubulin
-
Recptortubulin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1281816-04-3
-
Formula Weight1103.71
-
Molecular FormulaC53H75ClN6O15S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (90.60 mM)
-
SMILESC[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCSC5CC(=O)N(C5=O)CC6CCC(CC6)C(=O)NCCCC[C@@H](C(=O)O)N)C)\C)OC)(NC(=O)O2)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
molnova catalog
related products
-
Indibulin
Indibulin is a synthetic small molecule with antimitotic and potential antineoplastic activities.Indibulin ?an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity.
-
Tubulin inhibitor 6
Tubulin inhibitor 6 is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 6 exhibits submicromolar antiproliferative activity.
-
Vinflunine
The behavior of vinflunine in routine clinical practice resembles that of the pivotal phase III randomized study. Vinflunine（VFL）-EPR combination is feasible with manageable toxicity.
